Michael B Wheeler, PhD

The Wheeler lab employs a systems-physiology approach to research using innovative high-throughput techniques, incorporating mass-spectrometry and the membrane yeast two-hybrid system. This approach enables the Wheeler lab to perform powerful screens capable of revealing novel targets at an unprecedented rate. These screens are complemented by primary research that utilizes primary cells, cell lines and mouse models to ensure the results are biologically relevant. The lab focuses on two exciting research streams:
  • Assessing the Diabetic Effect on Metabolism in Humans using Metabolomics
    The Wheeler lab is exploring the use of metabolomics as a tool to directly assess the diabetic effect on metabolism in humans. Metabolomics is a recent technological advance that characterizes metabolites, the final compounds of chemical reactions and those most relevant to metabolic diseases such as diabetes. This approach forms the basis of multiple predictive- and causative-oriented investigations in our lab for gestational and type 2 diabetes.
  • Identification of GLP-1R Interactors as Potential Drug Targets for Type II Diabetes
    Using high-throughput technologies, incorporating mass spectrometry and MYTH screening, the Wheeler lab has identified a large number proteins that interact with the glucagon like peptide-1 receptor (GLP-1R) in a variety of tissues, including mouse and human islets. Following the identification and verification of GLP-1R interactors, members of the Wheeler lab characterize potential functional changes to glucose stimulated insulin secretion, GLP-1 binding, and proliferation and survival. Ultimately, candidate GLP-1R interactors that elicit significant functional changes are selected for further mechanistic studies. Identifying and characterizing GLP-1R interactors may reveal potential drug targets that can be utilized to improve the lives of those living with type 2 diabetes.
Drug Discov Today. 2019 May 31;:
Khan SR, Manialawy Y, Wheeler MB, Cox BJ
J Mech Behav Biomed Mater. 2019 Mar 22;95:21-33
Dewey MJ, Johnson EM, Weisgerber DW, Wheeler MB, Harley BAC
Nutr Diabetes. 2019 Mar 19;9(1):11
Desai T, Koulajian K, Ivovic A, Breen DM, Luu L, Tsiani EL, Wheeler MB, Giacca A
Metabolomics. 2018 Aug 25;14(9):113
Rubessa M, Ambrosi A, Gonzalez-Pena D, Polkoff KM, Wheeler MB
Diabetologia. 2019 Feb 08;:
Khan SR, Mohan H, Liu Y, Batchuluun B, Gohil H, Al Rijjal D, Manialawy Y, Cox BJ, Gunderson EP, Wheeler MB
Diabetologia. 2019 Jan 15;:
Khan SR, Mohan H, Liu Y, Batchuluun B, Gohil H, Al Rijjal D, Manialawy Y, Cox BJ, Gunderson EP, Wheeler MB
Mol Biol Rep. 2018 Dec 11;:
Rubessa M, Lotti SN, Kandel ME, Popescu G, Wheeler MB
FASEB J. 2018 Dec 03;:fj201801397R
Untereiner A, Abdo S, Bhattacharjee A, Gohil H, Pourasgari F, Ibeh N, Lai M, Batchuluun B, Wong A, Khuu N, Liu Y, Al Rijjal D, Winegarden N, Virtanen C, Orser BA, Cabrera O, Varga G, Rocheleau J, Dai FF, Wheeler MB
Res Vet Sci. 2018 Nov 12;122:22-28
Correia HHV, Vieira LA, Mielgo CM, Paes VM, Alves BG, Silva JRV, Wheeler MB, Rodrigues APR, Figueiredo JR
Diabetes Obes Metab. 2018 Jul 30;:
Mohan H, Brandt SL, Kim JH, Wong F, Lai M, Prentice KJ, Al Rijjal D, Magomedova L, Batchuluun B, Burdett E, Bhattacharjee A, Cummins CL, Belsham DD, Cox B, Liu Y, Wheeler MB



Professor, University of Toronto, Department of Physiology, Faculty of Medicine